Vitamin C Reverses Depression-Like Behavior in Female Mice via D2 Receptors

Reevaluating Ascorbic Acid in Psychiatric Care

Major depressive disorder disproportionately affects women, yet treatment options for female-specific conditions like perinatal depression remain limited by delayed efficacy and adverse side effect profiles. Emerging clinical evidence increasingly links oxidative stress (a cellular imbalance between reactive oxygen species and antioxidant defenses) to the pathophysiology of depression, prompting renewed interest in antioxidant therapies [1, 2]. Ascorbic acid, commonly known as vitamin C, demonstrates neuromodulatory properties that improve mood and alleviate depressive symptoms; for example, a crossover trial of 48 women showed that 150 mg of ascorbic acid combined with 100 mg of oxaloacetate reduced premenstrual depression scores by 54.1% and anxiety by 51.4% [3]. Furthermore, an ongoing randomized controlled trial of 424 patients is exploring whether ascorbic acid can synergize with rapid-acting antidepressants like esketamine to mitigate post-miscarriage psychiatric vulnerabilities [4]. Building on this clinical foundation, a recent preclinical study in female mice demonstrated that a single 200 mg/kg dose of ascorbic acid rapidly reversed stress-induced transcriptional alterations in 104 genes within the medial prefrontal cortex, specifically restoring the dopamine D2 receptor pathway to exert antidepressant effects within 24 hours [5].

Rapid Behavioral Rescue in Stress-Exposed Mice

The lifetime prevalence of depression is significantly higher in women, yet therapies for female-specific conditions like perinatal depression are severely limited by a lack of antidepressants that balance rapid efficacy with maternal safety. To address this clinical gap, researchers evaluated whether ascorbic acid, a widely used nutritional supplement and perinatal therapeutic agent, could serve as a targeted treatment. The study utilized a chronic restraint stress mouse model, a standard laboratory method used to simulate severe environmental stressors, to induce depression-like behaviors in adult female C57BL/6 mice over a 14-day period. Following the stress protocol, the researchers administered a single 200 mg/kg dose of ascorbic acid intraperitoneally (via injection into the abdominal cavity) to the mice exhibiting depressive phenotypes. The behavioral response was immediate and robust, as vitamin C rapidly ameliorated depression-like phenotypes in the stress-exposed female mice within 24 hours of the injection. To quantify anhedonia, a core depressive symptom characterized by a reduced ability to experience pleasure, the investigators used the sucrose preference test to track the animals' interest in sweetened water. This behavioral assay indicated that the antidepressant effect of vitamin C lasted for more than 72 hours. For practicing physicians, these behavioral outcomes highlight the potential of high-dose ascorbic acid to provide rapid and sustained symptom relief in stress-induced depressive states, offering a highly tolerable alternative or adjunct for vulnerable patient populations.

Reversing Transcriptional Alterations in the Prefrontal Cortex

To understand how ascorbic acid exerts these rapid behavioral effects, the researchers explored the underlying mechanisms using RNA sequencing to evaluate gene expression and western blotting to measure protein levels. They focused their analysis on the medial prefrontal cortex, a brain region critical for mood regulation, decision-making, and executive function. Transcriptome sequencing analysis, a technique that measures the expression levels of thousands of genes simultaneously, revealed that vitamin C reversed chronic restraint stress-induced transcriptional alterations in 104 genes in the medial prefrontal cortex of female mice. Crucially, this specific cluster of 104 genes included the dopamine receptor D2. For clinicians, this points to a highly specific molecular target, suggesting that ascorbic acid does not merely act as a general systemic antioxidant but actively modulates specific neurotransmitter pathways impaired by chronic stress. To map the broader impact of these genetic changes, the investigators utilized a protein-protein interaction network analysis, a computational method that maps how different proteins work together in cellular pathways. This analysis revealed functional linkages between the dopamine D2 receptor and other vitamin C-regulated stress-sensitive genes. This interconnected network indicates that restoring dopamine D2 receptor signaling may trigger a cascade of downstream effects, stabilizing multiple stress-response pathways simultaneously. By pinpointing these exact molecular linkages, the study provides a biological rationale for how a simple nutritional supplement can produce profound, rapid antidepressant effects at the cellular level.

Restoring the Dopamine D2 Receptor Pathway

To confirm the functional consequences of the observed transcriptional changes, the researchers analyzed protein expression in the medial prefrontal cortex. Western blotting, a laboratory technique used to detect and quantify specific proteins, confirmed that chronic restraint stress suppressed the D2R-ERK1/2-CREB-BDNF pathway in the medial prefrontal cortex. This vital signaling cascade links the dopamine D2 receptor (D2R) to brain-derived neurotrophic factor (BDNF) via extracellular signal-regulated kinases (ERK1/2) and the cAMP response element-binding protein (CREB), ultimately driving synaptic plasticity and neuronal survival. Following the administration of ascorbic acid, this molecular deficit was reversed. Specifically, the suppression of the D2R-ERK1/2-CREB-BDNF pathway in the medial prefrontal cortex was effectively rescued by vitamin C. For clinicians, this demonstrates that ascorbic acid directly rehabilitates a critical neurotrophic network known to be blunted in major depressive disorder. To prove that this dopamine receptor activation was necessary for the observed behavioral improvements, the investigators utilized a targeted pharmacological intervention. They found that the antidepressant effect of vitamin C was antagonized by sulpiride, a medication that selectively blocks dopamine D2 receptors. By inhibiting this receptor, sulpiride completely neutralized the therapeutic benefits of ascorbic acid, confirming that the dopamine D2 receptor is the primary mediator of the treatment response. Ultimately, the findings suggest that vitamin C may serve as an ideal candidate for the treatment of depression in females, potentially through the restoration of the D2R-BDNF pathway. Because ascorbic acid is already a widely available, well-tolerated nutritional supplement with an established safety profile in perinatal care, these results provide a strong biological rationale for translating this targeted neuroplasticity rescue into clinical trials for female-specific depressive disorders.

References

1. Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clinical Interventions in Aging. 2018. doi:10.2147/cia.s158513

2. Liu T, Zhong S, Liao X, et al. A Meta-Analysis of Oxidative Stress Markers in Depression. PLoS ONE. 2015. doi:10.1371/journal.pone.0138904

3. Tully L, Humiston J, Cash A. Oxaloacetate reduces emotional symptoms in premenstrual syndrome (PMS): results of a placebo-controlled, cross-over clinical trial.. Obstetrics & gynecology science. 2020. doi:10.5468/ogs.2020.63.2.195

4. Ke Z, Zhang Y, Cai B, et al. Ascorbic Acid and Esketamine for Mental Disorders in Women with Miscarriage: A Randomized Controlled Double-Blind Trial Protocol.. Neuropsychiatric disease and treatment. 2025. doi:10.2147/NDT.S516355

5. Luo M, Li Y, Gao X, Yang Y, Jiang S. Single administration of vitamin C produces rapid antidepressant-like effects in female mice: A possible role of dopamine D2 receptor signalling.. Brain research. 2026. doi:10.1016/j.brainres.2026.150181